The EU-CARDIOPROTECTION COST Action (CA16225) is a pan-European research network of leading experts in experimental and clinical cardioprotection, whose overall aim is to improve the translation of novel experimental cardioprotective therapies into the clinical setting for patient benefit.
5th EU-CARIDOPROTECTION COST Action CA16225 meeting was held in Oslo Sept 16-18 2019September 24, 2019 | General
Our 5th EU-CARIDOPROTECTION COST Action CA16225 meeting was held in Oslo Sept 16-18 2019 with nearly 90 attendees in total. We had a very successful and enjoyable meeting both scientifically and socially. On the first day we held a workshop on animal models used to investigate cardioprotection with a focus on co-morbidities and co-medications which […]
5th EU-CARDIOPROTECTION COST Action MC and WG Meeting, September 16-18, 2019 in OsloJune 28, 2019 | General
Welcome to the 5th EU-CARDIOPROTECTION COST Action MC and WG Meeting, September 16-18th, 2019 in Oslo, Norway at Oslo University Hospital Rikshospitalet! The first day of the meeting is a workshop on animal models and co-morbidities, which is an exciting topic for every researcher in targeting cardiac ischemia/reperfusion injury and will give valuable insights when choosing […]
Translating Cardioprotection for Patient BenefitApril 17, 2019 | General
Acute myocardial infarction and the subsequent development of heart failure are among the leading causes of death and disability globally. The most effective treatment for limiting infarct size and preventing subsequent heart failure is timely interventional or surgical reperfusion, but even then, mortality and morbidity remain significant (1). Accordingly, new treatments are required, but the […]